Nivolon (Nebivolol Hydrochloride)

• Nivolon (nebivolol) is used to manage conditions within the cardiovascular disease pathway, primarily hypertension.
• Hypertension: lowers elevated blood pressure in adults
• Heart failure (reduced ejection fraction): improves cardiac output and reduces symptoms of fluid overload
• Elderly patients with hypertension: provides effective blood‑pressure control with a favorable tolerability profile

• Nebivolol acts as a selective β1‑adrenergic receptor antagonist, reducing heart rate and myocardial contractility. In addition, it stimulates endothelial nitric‑oxide synthase, increasing nitric‑oxide release which causes vasodilation. The combined β1‑blockade and nitric‑oxide‑mediated vasorelaxation result in decreased systemic vascular resistance and lowered arterial pressure.

Nebivolol may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects

• Headache: mild to moderate headache reported.
• Dizziness or light‑headedness.
• Fatigue or tiredness.
• Bradycardia: slower than normal heart rate.

Serious or Rare Side Effects

• Severe bradycardia or heart block: may require medical attention.
• Bronchospasm or worsening asthma symptoms.
• Allergic reactions: rash, angioedema, or anaphylaxis.

When prescribing nebivolol, clinicians should consider several precautionary measures to ensure safe use.

• Monitor blood pressure: check regularly after initiation or dose changes.
• Assess heart rate: watch for bradycardia, especially in patients with conduction disorders.
• Use caution in asthma or chronic obstructive pulmonary disease: β‑blockade may precipitate bronchospasm.
• Avoid abrupt discontinuation: sudden stop can lead to rebound hypertension.
• Pregnancy category B: discuss potential risks with prescriber before use in pregnant or breastfeeding women.
• Store below 25°C: keep in the original container, protect from moisture and direct light.

Nebivolol can interact with other medicines, and the significance of the interaction determines the management approach.

Major Interactions (Avoid)

• Non‑selective beta‑blockers (e.g., propranolol): additive bradycardia and hypotension.
• Calcium‑channel blockers verapamil or diltiazem: increased risk of AV‑block and severe bradycardia.
• Clonidine: abrupt withdrawal after combined use may cause severe rebound hypertension.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: may enhance hypotensive effect, requiring blood‑pressure monitoring.
• Diuretics: additive blood‑pressure lowering, monitor electrolytes and volume status.
• Antidiabetic agents (insulin, sulfonylureas): β‑blockade may mask hypoglycaemia symptoms, adjust monitoring.